A 41-Year-Old Woman Presents With Cough and Dyspnea

Poll

A 41-year-old woman presents with cough and dyspnea. After further evaluation, a bronchial mass is identified and a biopsy is performed. What is your diagnosis?

A 41-year-old woman presents with cough and dyspnea. After further evaluation, a bronchial mass is identified. According to the histopathology image below, what is your diagnosis?

What is your diagnosis?

A. Adenocarcinoma
B. Squamous cell carcinoma
C. Leiomyoma
D. Small cell carcinoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
Related Content
An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
August 4th 2025
Article

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
August 4th 2025
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
August 4th 2025
Article

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
August 4th 2025
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved a 1-year event-free survival.

OST-HER2 Shows Significant EFS Improvement in Metastatic Lung Osteosarcoma

Roman Fabbricatore
August 4th 2025
Article

A total of 35% of patients with fully resected metastatic lung osteosarcoma treated with OST-HER2 achieved 1-year event-free survival.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

The Role of Artificial Intelligence in Enhancing Precision Medicine for NSCLC

Puneet Modgil, MD
August 4th 2025
Article

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.